"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter.

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and ...

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD. In this video, Daniel Kwon, MD, discusses the impact of the JNCI Cancer Spectrum paper, “Germline ...

Epigenomic cfDNA profiling may predict PSMA expression and response to Lutetium-PSMA in mCRPC patients, offering a non-invasive alternative to PSMA-PET scans. The study showed comparable hazard ratios ...

Mindfulness principles, such as intentionality and presence, can enhance surgeons' well-being and career longevity, addressing high burnout rates. Mindfulness is not a cure-all but helps mitigate ...

Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.

“I think as urologists, we need to become more comfortable with the female pelvic floor,” says Ava Saidian, MD. In this video, Ava Saidian, MD, highlights the importance of preventing pelvic prolapse ...

UGN-101 demonstrated a median duration of response of 47.8 months in patients with low-grade UTUC achieving complete response. The OLYMPUS trial emphasized kidney-sparing techniques, with 75% of ...

In this video, Jason M. Hafron, MD, explains how PSMA-PET has enabled the use of more targeted treatment approaches in the management of oligometastatic prostate cancer. Hafron is the chief medical ...

Kiwi extract, a natural collagenase, offers a medium-effect therapy with fewer side effects compared to Xiaflex. Peptides show potential as collagenase agents, but their safety profile is currently ...